- Home
- AMSF vs VIR Comparison
AMSF vs VIR Comparison
Compare AMSF & VIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AMSF
- VIR
- Stock Information
- Founded
- AMSF 1985
- VIR 2016
- Country
- AMSF United States
- VIR United States
- Employees
- AMSF N/A
- VIR N/A
- Industry
- AMSF Accident &Health Insurance
- VIR Biotechnology: Pharmaceutical Preparations
- Sector
- AMSF Finance
- VIR Health Care
- Exchange
- AMSF Nasdaq
- VIR Nasdaq
- Market Cap
- AMSF 984.1M
- VIR 1.0B
- IPO Year
- AMSF 2005
- VIR 2019
- Fundamental
- Price
- AMSF $51.24
- VIR $7.27
- Analyst Decision
- AMSF Buy
- VIR Buy
- Analyst Count
- AMSF 2
- VIR 5
- Target Price
- AMSF $59.50
- VIR $36.40
- AVG Volume (30 Days)
- AMSF 134.8K
- VIR 1.2M
- Earning Date
- AMSF 02-19-2025
- VIR 02-20-2025
- Dividend Yield
- AMSF 2.90%
- VIR N/A
- EPS Growth
- AMSF N/A
- VIR N/A
- EPS
- AMSF 3.21
- VIR N/A
- Revenue
- AMSF $315,182,000.00
- VIR $78,618,000.00
- Revenue This Year
- AMSF N/A
- VIR N/A
- Revenue Next Year
- AMSF $0.88
- VIR N/A
- P/E Ratio
- AMSF $15.88
- VIR N/A
- Revenue Growth
- AMSF 2.81
- VIR N/A
- 52 Week Low
- AMSF $41.97
- VIR $6.56
- 52 Week High
- AMSF $60.24
- VIR $13.09
- Technical
- Relative Strength Index (RSI)
- AMSF 32.75
- VIR 42.92
- Support Level
- AMSF $50.61
- VIR $7.22
- Resistance Level
- AMSF $51.98
- VIR $7.64
- Average True Range (ATR)
- AMSF 0.94
- VIR 0.35
- MACD
- AMSF -0.16
- VIR -0.01
- Stochastic Oscillator
- AMSF 14.93
- VIR 30.43
About AMSF AMERISAFE Inc.
AMERISAFE Inc is a specialty provider of workers' compensation insurance to employers engaged in hazardous industries, mainly construction, trucking, manufacturing, oil and gas, and agriculture. The company generates a majority of its revenue in the form of premiums.
About VIR Vir Biotechnology Inc.
Vir Biotechnology Inc is an immunology company focused on combining cutting-edge technologies to treat and prevent serious infectious diseases and other serious conditions, including viral-associated diseases. Through internal development, collaborations, and acquisitions, it has four technology platforms, focused on antibodies, T cells, innate immunity, and small interfering ribonucleic acid, or siRNA. The company's pipeline consists of product candidates targeting hepatitis B, HBV, influenza A, human immunodeficiency virus, HIV, and tuberculosis, or TB. Its revenue sources are collaboration revenue, contract revenue, grant revenue, and license revenue.